Ivonescimab's long-term data shows reduced benefit in Chinese lung cancer patients
Summit Therapeutics and Akeso's ivonescimab received approval in China for first-line treatment of certain lung cancers. However, updated follow-up data indicate a smaller benefit than previously observed. The approval comes amid concerns about the drug's long-term efficacy.
Related stories
Ivonescimab's progression-free survival benefit fades over time · Cancer research
Fatal outcome surfaces in Chinese gene therapy study, raising transparency concerns · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China.” Browse more stories.